NewAmsterdam Pharma Q2 2025 Earnings Results & Report

NewAmsterdam Pharma EPS Results

• Actual EPS: -$0.15
• Consensus EPS: -$0.52
• Beat/Miss: Beat by +$0.37
• One Year Ago EPS: N/A
• EPS Beat Rate: 3 of last 8 quarters

NewAmsterdam Pharma Revenue Results

• Actual Revenue: $19.15 million
• Expected Revenue: $1.44 million
• Beat/Miss: Beat by +$17.71 million
• YoY Revenue Growth: N/A

NewAmsterdam Pharma (NASDAQ:NAMS) is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, with an emphasis on improving the treatment of dyslipidemia and reducing cardiovascular risk. The company’s lead investigational product is obicetrapib, an oral cholesteryl ester transfer protein (CETP) inhibitor designed to lower low-density lipoprotein cholesterol and potentially address other lipid-related abnormalities.

Obicetrapib is being studied as an adjunct to existing lipid-lowering therapies, including in patients who have not achieved adequate cholesterol control and people with heterozygous familial hypercholesterolemia. NewAmsterdam has conducted late-stage clinical trials, including the BROADWAY and BROOKLYN studies, to evaluate the product’s efficacy and safety. As a clinical-stage company, NewAmsterdam does not yet have an approved commercial product.

NewAmsterdam Pharma was established through the combination of businesses involved in the development of obicetrapib and became publicly traded on the Nasdaq under the symbol NAMS following a business combination with Frazier Lifesciences Acquisition Corporation in 2022. The company is led by Chief Executive Officer Michael Davidson, M.D., and conducts its clinical development activities across international markets.